Description
Hydroxyurea exhibits anticancer chemotherapeutic and antiviral activities; it inhibits ribonucleotide reductase, limiting deoxyribonucleotide production and inhibiting DNA synthesis. This compound also treats sickle cell anemia, as it increases NO levels in blood through binding of hemoglobin and stimulates production of fetal hemoglobin which is not affected by the sickle-cell gene mutation. It also treats myeloproliferative disorders and chronic myelogenous leukemia (CML)